Get all your news in one place.
100's of premium titles.
One app.
Start reading
Evening Standard
Evening Standard
Health
Storm Newton

REVEALED: Alzheimer s drugs make no meaningful difference to patients say researchers - The Real Truth

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s (Alamy/PA) -

Drugs that are said to slow the progression of Alzheimer’s disease “make no meaningful difference to patients” while increasing the risk of swelling and bleeding in the brain, according to a new review.

The effects of the medicines on those with early-stage Alzheimer’s and dementia were “either absent or consistently small”, researchers said.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.